D. Noe

发表

Selecting a diagnostic study's cutoff value by using its receiver operating characteristic curve.

D. Noe, 1983, Clinical chemistry.

Reduction in the plasma clearance rate of warfarin induced by cimetidine.

D. Noe, W. Bell, K. Anderson, 1986, Archives of internal medicine.

Parameter Estimation and Reporting in Noncompartmental Analysis of Clinical Pharmacokinetic Data

D. Noe, 2020, Clinical pharmacology in drug development.

D. Noe, 2001 .

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

E K Rowinsky, L. Grochow, D. Ettinger, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is dose normalization to weight or body surface area useful in adults?

L. Grochow, D. Noe, C. Baraldi, 1990, Journal of the National Cancer Institute.

A Phase I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate on an 120-h Infusion Schedule 1

L. Grochow, D. Noe, M. Carducci, 2001 .

Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.

D. Noe, O. Colvin, G. Vogelsang, 1989, Drug metabolism and disposition: the biological fate of chemicals.

Laboratory Medicine: The Selection and Interpretation of Clinical Laboratory Studies

D. Noe, D. A. Noe, R. Rock, 1994 .

Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.

L. Grochow, D. Noe, O. Colvin, 1995, Cancer research.

Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.

K. Venkatakrishnan, D. Noe, T. Marbury, 2014, British journal of clinical pharmacology.

A body surface area nomogram based on the formula of Gehan and George.

D. Noe, 1991, Journal of pharmaceutical sciences.

Chapter 9 TISSUE INJURY

D. Noe, 2001 .

Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione.

D. Noe, J. Hilton, O. Colvin, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.

A. Ribas, D. Noe, J. Gómez-Navarro, 2007, The oncologist.

A Phase I/II Evaluation of Oral L‐2‐Oxothiazolidine‐4‐Carboxylic Acid in Asymptomatic Patients Infected with Human Immunodeficiency Virus

M. Lederman, D. Noe, P. Barditch-Crovo, 1998, Journal of clinical pharmacology.

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

L. Grochow, D. Noe, S. Khor, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

L. Grochow, D. Noe, R. Donehower, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.

D. Noe, M. Zahurak, R. Donehower, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

L. Grochow, D. Ettinger, D. Noe, 1990, Cancer research.

A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors

D. Noe, D. Sullivan, S. Moulder, 2004, Clinical Cancer Research.

Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine

M. Citardi, D. Noe, R. Donehower, 2005, Journal of Cancer Research and Clinical Oncology.

Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination

M. Gilbert, M. Citardi, D. Noe, 1991 .

Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.

L. Grochow, D. Ettinger, D. Noe, 1987, Cancer research.

Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.

D. Noe, W. Bell, P. Sholar, 1985, The American journal of medicine.

Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals.

D. Noe, J. Levin, W. Bell, 1986, Blood.

A mathematical model of coagulation factor VIII kinetics.

D. Noe, 1996, Haemostasis.

The partitioning of phosphoramide mustard and its aziridinium ions among alkylation and P-N bond hydrolysis reactions.

D. Noe, O. Colvin, F. Hausheer, 1998, Journal of medicinal chemistry.

Simple approximate formulas for calculating the time to clear drug and the time to accumulate drug when the plasma disposition curve of the drug is multiexponential

D. Noe, 1994, Journal of Pharmacokinetics and Biopharmaceutics.

A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

L. Grochow, D. Noe, M. Carducci, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.

K. Venkatakrishnan, D. Noe, T. Marbury, 2014, British journal of clinical pharmacology.

Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.

E. Winer, D. Ettinger, D. Noe, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Direct spectrophotometry of serum hemoglobin: an Allen correction compared with a three-wavelength polychromatic analysis.

V. Weedn, D. Noe, W. Bell, 1984, Clinical chemistry.

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

J. Verweij, D. Noe, P. Schöffski, 2005, Cancer Chemotherapy and Pharmacology.

Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits.

D. Noe, P. Murphy, J. Siegel, 1989, The American journal of physiology.

Neonatal hypocalcemia and related conditions.

D. Noe, 1981, Clinics in laboratory medicine.

Drug kinetics in low-flux (small) anatomic compartments.

D. Noe, K. Kumor, 1983, Journal of pharmaceutical sciences.

Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans.

E K Fishman, E K Rowinsky, D. Ettinger, 1993, Cancer research.

Selective enhancement of cellular oxidative stress by chloroquine: implications for the treatment of glioblastoma multiforme.

D. Noe, S. Toler, Amarnath Sharma, 2006, Neurosurgical focus.

Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.

L. Grochow, D. Noe, M. Zahurak, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma.

K. Venkatakrishnan, J. Nemunaitis, D. Noe, 2013 .

Platelet counts during rapid massive transfusion

D. Noe, P. Sohmer, S. M. Graham, 1982, Transfusion.

A Phase I and Pharmacologic Study of Pyrazoloacridine and Cisplatin in Patients with Advanced Cancer

D. Noe, R. Donehower, A. Adjei, 2003, Investigational New Drugs.

A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics

L. Grochow, D. Ettinger, D. Noe, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.

L. Grochow, D. Ettinger, D. Noe, 1990, Cancer research.

Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.

E K Rowinsky, L. Grochow, D. Ettinger, 1989, Journal of the National Cancer Institute.

Clinical and pharmacologic reappraisal of dichloromethotrexate.

L. Grochow, D. Ettinger, D. Noe, 1988, Journal of the National Cancer Institute.

Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity.

L. Grochow, D. Ettinger, D. Noe, 1988, Journal of the National Cancer Institute.

A kinetic analysis of fibrinogenolysis during plasminogen activator therapy

W R Bell, D. Noe, D A Noe, 1987, Clinical pharmacology and therapeutics.

A model of the heterogeneity of red cell hemoglobin concentration.

D. Noe, W. Bell, Dennis A. Noe, 1985, Computers and biomedical research, an international journal.

Thyroxine and Thyroxine-Binding Globulin: Discriminant Formulae for the Separation of the Diagnostic Classes of Thyroid Function

D. Noe, 1984, Annals of clinical biochemistry.

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.

L. Grochow, D. Noe, R. Donehower, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390)1

L. Grochow, D. Ettinger, D. Noe, 2006 .

A pharmacokinetic–pharmacodynamic model of heart rate during cocaine administration in humans

D. Noe, D A Noe, K M Kumor, 1991, Clinical pharmacology and therapeutics.

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2

E. Sausville, K. Venkatakrishnan, P. LoRusso, 2013, Investigational New Drugs.

Chapter 7 ORGAN FUNCTION

D. Noe, 2001 .

The Logic of laboratory medicine : principles for use of the clinical laboratory

D. Noe, 1985 .

137 A phase I study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients with advanced solid tumors

A. Tolcher, D. Noe, D. Healey, 2004 .